Poulikos I. Poulikakos

This study identifies ELV-3111, a Type 1 RAF inhibitor that selectively suppresses MAPK and tumor growth by exploiting distinct binding kinetics, showing efficacy in RAS-mutant and BRAF-mutant models.

The paper shows RAF/MEK glues enable full-dose combination with pan-RAF inhibitors, enhancing tumor-selective MAPK inhibition and tumor regression in RAS-mutant models.

This study evaluates the signaling inhibition index (SII) of various RAS-targeted inhibitors across RAS-mutant and wild-type models, revealing significant variability in their effectiveness and selectivity.